As it stands, there will be no updated COVID vaccine approved for the upcoming fall/winter 2025 vaccination season, and neither Moderna nor Pfizer/BioNTech has guided that they will run trials to ...

A new study shows that previous treatments with monoclonal antibodies may impact your future immune defenses against Covid-19.

Adam C. Welch, PharmD, MBA, FAPhA: So if these monoclonal antibodies are relatively short as far as the duration of protection that they provide and we’re not quite sure when the RSV ...

Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a ...

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...

This is the first authorization for a pre-exposure prophylaxis therapy in the U.S., though the FDA has already authorized some monoclonal antibodies for post-exposure prophylaxis.

A new study expands the understanding of the impact of receiving a prophylactic monoclonal antibody infusion, as well as other variables, on the endogenous immune response to complete COVID-19 ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system ...

However, citing a “finite amount of resources,” LeBaron noted that RUMC is not yet offering monoclonal antibody treatment on the recently-enabled prophylactic basis.

Monoclonal antibodies are the best option against SARS-CoV-2 for oncohematology patients, although viral variants may reduce the efficacy of these treatments.

Monoclonal antibodies for routine prevention in immunocompromised people—not just prevention after exposure to someone infected—are likely coming down the pipeline too.